Media Center
Press Releases

Press Releases

06 Dec 16
Global neurodegenerative drugs market set to hit $45 billion by 2022, says GBI Research

The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%, according to business intelligence provider GBI Research.

Read post
01 Dec 16
Type 2 diabetes drugs may be a valuable resource in the treatment of Alzheimer’s disease, says GBI Research

Recent findings have shown that type 2 diabetes mellitus (T2DM) drugs could be used to alleviate symptoms among Alzheimer’s disease patients, or even exert potential disease-modifying effects, according to business intelligence firm GBI Research.

Read post
29 Nov 16
Asia-Pacific anti-hypertensive therapeutics market to hit $27 billion by 2022, despite low innovation, says GBI Research

The market for anti-hypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea, and Japan, is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%, according to business intelligence provider GBI Research.

Read post
28 Nov 16
Type 2 diabetes mellitus market ripe with opportunities for potential investors, says GBI Research

The increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, caused by rising prevalence of the disease, has resulted in a large and competitive market landscape. There are a number of drugs competing for different market segments, across multiple lines of therapy, according to business intelligence provider GBI Research.

Read post
23 Nov 16
Healthcare companies must embrace new funding sources as venture investment continues to decline, says GBI Research

Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early-stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, says business intelligence provider GBI Research.

Read post